Neurotech International
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 23 Jan 2026
- Reported shorts
- 143.2K
- Shares on issue
- 1.296B
Neurotech International (NTI) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $44.6KM (source: ASX (Markit))vs $238 (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$6.5MM (source: ASX (Markit))vs −$10.6M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.005T (source: Derived: trailing 12 months at year end)vs −$0.010 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- n/mFY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Annual Report (Typeset), 5 Oct 2026
Neurotech International reported a net loss of $6.5 million for FY2026, narrowing from the prior year's $10.6 million loss as it advanced its lead drug candidate NTI164 into a Phase III trial for autism spectrum disorder. No dividend was paid. The company provided no forward guidance but highlighted progress in clinical development and regulatory milestones.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −25,416.1%
- Net margin
- −14,647.2%
- FCF margin
- −9,462.8%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $44.6KM (source: ASX (Markit)) | $238 | $2.0K | $6.0K |
| Gross profit | n/a | $238 | −$5.9K | $6.0K |
| Operating income | −$11.3MT (source: Derived: trailing 12 months at year end) | −$13.2M | −$8.4M | −$9.0M |
| EBITDA | −$11.3MT (source: Derived: trailing 12 months at year end) | −$13.2M | −$8.4M | −$9.0M |
| EBIT | −$11.3MT (source: Derived: trailing 12 months at year end) | −$13.2M | −$8.4M | −$9.0M |
| Pretax income | −$6.5MT (source: Derived: trailing 12 months at year end) | −$10.6M | −$5.1M | −$7.8M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | $0 | $0 | $0 |
| NPAT | −$6.5MM (source: ASX (Markit)) | −$10.6M | −$5.1M | −$7.8M |
| Net interest income | $44.6KT (source: Derived: trailing 12 months at year end) | $137.1K | $158.2K | $59.6K |
| EPS basic | −$0.005T (source: Derived: trailing 12 months at year end) | −$0.010 | −$0.006 | −$0.010 |
| EPS diluted | −$0.005T (source: Derived: trailing 12 months at year end) | −$0.010 | −$0.006 | −$0.010 |
| Shares | n/a | 1.05B | 1.02B | 873.9M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Annual Report (Typeset)Annual Report5 Oct 2026via asx_announcements
- Appendix 4E & Annual Report to shareholdersAnnual Results26 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Appendix 4D & Half Year ReportHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Oct 2025via asx_announcements
- Annual Report (Typeset)Annual Report16 Oct 2025via asx_announcements
- Appendix 4E & Annual Report to shareholdersAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
Showing 10 of 20 reports